{"filing":{"accession_number":"0001129928-26-000055","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"oncy-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000055/oncy-20260910.htm"},"events":[{"id":32557,"run_id":29915,"accession_number":"0001129928-26-000055","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Oncolytics disclosed positive preclinical study results for pelareorep in combination with a pan-RAS inhibitor in colorectal cancer, demonstrating maintained drug activity and biological compatibility. This is a material operational/strategic milestone for a clinical-stage biotech company that supports continued development of a key therapeutic candidate and informs future clinical trial design. While not a specific named event type, this is clearly an operational disclosure of significant scientific and strategic importance to the company's pipeline.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35755,"accession_number":"0001129928-26-000055","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Oncolytics disclosed positive preclinical study results for pelareorep in combination with a pan-RAS inhibitor in colorectal cancer, demonstrating maintained drug activity and biological compatibility. This is a material operational/strategic milestone for a clinical-stage biotech company that supports continued development of a key therapeutic candidate and informs future clinical trial design. While not a specific named event type, this is clearly an operational disclosure of significant scientific and strategic importance to the company's pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:18:37.602573+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35755,"accession_number":"0001129928-26-000055","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Oncolytics disclosed positive preclinical study results for pelareorep in combination with a pan-RAS inhibitor in colorectal cancer, demonstrating maintained drug activity and biological compatibility. This is a material operational/strategic milestone for a clinical-stage biotech company that supports continued development of a key therapeutic candidate and informs future clinical trial design. While not a specific named event type, this is clearly an operational disclosure of significant scientific and strategic importance to the company's pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T12:18:37.602573+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-09-10"}]}